Highlights in Chronic Kidney Disease From American Society of Nephrology Kidney Week 2020 Reimagined

Jeffrey Silberzweig, MD


November 13, 2020

Dr Jeffrey Silberzweig, chief medical officer at the Rogosin Institute, reports on key presentations from the American Society of Nephrology Kidney Week 2020, focusing on advances in chronic kidney disease (CKD).

The care of patients with proteinuric renal disease and type 2 diabetes is undergoing a paradigm shift because of expanding data regarding SGLT2 inhibitors. Dr Silberzweig comments on the DAPA-CKD trial, which offered promising results in the use of dapagliflozin, an SGLT2 inhibitor, in patients with heart failure and reduced ejection fraction.

He also discusses improved outcomes for CKD trial patients with anemia, achieved by the use of novel oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs).

This year also proved robust in research dealing with ethnic disparities in the treatment of CKD patients. Dr Silberzweig comments on a study examining the impact of the race multiplier in the estimated glomerular filtration rate (eGFR) on care delivery among African-American CKD patients. Of 2225 African-American patients, 743 (33.4%) would be reclassified in this study to a more severe CKD stage if the race multiplier were removed.

Finally, Dr Silberzweig reports on patient care innovations that came out of the COVID-19 pandemic and which may have long-term benefits for patients. 


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.